239 related articles for article (PubMed ID: 27648712)
1. The Prognostic Value of Plasma YKL-40 in Patients With Chemotherapy-Resistant Ovarian Cancer Treated With Bevacizumab.
Boisen MK; Madsen CV; Dehlendorff C; Jakobsen A; Johansen JS; Steffensen KD
Int J Gynecol Cancer; 2016 Oct; 26(8):1390-8. PubMed ID: 27648712
[TBL] [Abstract][Full Text] [Related]
2. Phase II trial of nintedanib in patients with bevacizumab-resistant recurrent epithelial ovarian, tubal, and peritoneal cancer.
Secord AA; McCollum M; Davidson BA; Broadwater G; Squatrito R; Havrilesky LJ; Gabel AC; Starr MD; Brady JC; Nixon AB; Duska LR
Gynecol Oncol; 2019 Jun; 153(3):555-561. PubMed ID: 30929823
[TBL] [Abstract][Full Text] [Related]
3. Elevated preoperative plasma D-dimer level is a useful predictor of chemoresistance and poor disease outcome for serous ovarian cancer patients.
Liu P; Wang Y; Tong L; Xu Y; Zhang W; Guo Z; Ni H
Cancer Chemother Pharmacol; 2015 Dec; 76(6):1163-71. PubMed ID: 26542279
[TBL] [Abstract][Full Text] [Related]
4. Plasma YKL-40, as a prognostic tumor marker in recurrent ovarian cancer.
Dehn H; Høgdall EV; Johansen JS; Jørgensen M; Price PA; Engelholm SA; Høgdall CK
Acta Obstet Gynecol Scand; 2003 Mar; 82(3):287-93. PubMed ID: 12694127
[TBL] [Abstract][Full Text] [Related]
5. Prognostic importance of cell-free DNA in chemotherapy resistant ovarian cancer treated with bevacizumab.
Steffensen KD; Madsen CV; Andersen RF; Waldstrøm M; Adimi P; Jakobsen A
Eur J Cancer; 2014 Oct; 50(15):2611-8. PubMed ID: 25087181
[TBL] [Abstract][Full Text] [Related]
6. Measurements of adiposity as clinical biomarkers for first-line bevacizumab-based chemotherapy in epithelial ovarian cancer.
Slaughter KN; Thai T; Penaroza S; Benbrook DM; Thavathiru E; Ding K; Nelson T; McMeekin DS; Moore KN
Gynecol Oncol; 2014 Apr; 133(1):11-5. PubMed ID: 24680585
[TBL] [Abstract][Full Text] [Related]
7. A prognostic nomogram to predict overall survival in women with recurrent ovarian cancer treated with bevacizumab and chemotherapy.
Previs RA; Bevis KS; Huh W; Tillmanns T; Perry L; Moore K; Chapman J; McClung C; Kiet T; Java J; Chan J; Secord AA
Gynecol Oncol; 2014 Mar; 132(3):531-6. PubMed ID: 24472410
[TBL] [Abstract][Full Text] [Related]
8. Plasma YKL-40 as a biomarker for bevacizumab efficacy in patients with newly diagnosed glioblastoma in the phase 3 randomized AVAglio trial.
Boisen MK; Holst CB; Consalvo N; Chinot OL; Johansen JS
Oncotarget; 2018 Jan; 9(6):6752-6762. PubMed ID: 29467925
[TBL] [Abstract][Full Text] [Related]
9. Ascites predicts treatment benefit of bevacizumab in front-line therapy of advanced epithelial ovarian, fallopian tube and peritoneal cancers: an NRG Oncology/GOG study.
Ferriss JS; Java JJ; Bookman MA; Fleming GF; Monk BJ; Walker JL; Homesley HD; Fowler J; Greer BE; Boente MP; Burger RA
Gynecol Oncol; 2015 Oct; 139(1):17-22. PubMed ID: 26216729
[TBL] [Abstract][Full Text] [Related]
10. Independent radiologic review of AURELIA, a phase 3 trial of bevacizumab plus chemotherapy for platinum-resistant recurrent ovarian cancer.
Husain A; Wang Y; Hanker LC; Ojeda B; Anttila M; Breda E; Vuylsteke P; Pujade-Lauraine E
Gynecol Oncol; 2016 Sep; 142(3):465-70. PubMed ID: 27184721
[TBL] [Abstract][Full Text] [Related]
11. High plasma YKL-40 level in patients with ovarian cancer stage III is related to shorter survival.
Høgdall EV; Johansen JS; Kjaer SK; Price PA; Christensen L; Blaakaer J; Bock JE; Glud E; Høgdall CK
Oncol Rep; 2003; 10(5):1535-8. PubMed ID: 12883737
[TBL] [Abstract][Full Text] [Related]
12. Multiple genetic variants predict the progression-free survival of bevacizumab plus chemotherapy in advanced ovarian cancer: A retrospective study.
Gao J; Li F; Liu Z; Huang M; Chen H; Liao G; Meng J; Wang Q; Zhao H; Li C; Ji J; Cai S; Du N
Medicine (Baltimore); 2021 Sep; 100(35):e27130. PubMed ID: 34477158
[TBL] [Abstract][Full Text] [Related]
13. Histopathology predicts clinical outcome in advanced epithelial ovarian cancer patients treated with neoadjuvant chemotherapy and debulking surgery.
Muraji M; Sudo T; Iwasaki S; Ueno S; Wakahashi S; Yamaguchi S; Fujiwara K; Nishimura R
Gynecol Oncol; 2013 Dec; 131(3):531-4. PubMed ID: 24096109
[TBL] [Abstract][Full Text] [Related]
14. [Identification and prognostic value of differentially expressed proteins of patients with platinum resistance epithelial ovarian cancer in serum].
Wu WJ; Wang Q; Zhang W; Li L
Zhonghua Fu Chan Ke Za Zhi; 2016 Jul; 51(7):515-23. PubMed ID: 27465871
[TBL] [Abstract][Full Text] [Related]
15. Postoperative human epididymis protein 4 predicts primary therapy outcome in advanced epithelial ovarian cancer.
Vallius T; Hynninen J; Auranen A; Matomäki J; Oksa S; Roering P; Grènman S
Tumour Biol; 2017 Feb; 39(2):1010428317691189. PubMed ID: 28218038
[TBL] [Abstract][Full Text] [Related]
16. Prognostic and predictive value of YKL-40 in stage IIB-III melanoma.
Krogh M; Christensen I; Bouwhuis M; Johansen JS; Nørgaard P; Schmidt H; Hansson J; Suciu S; Eggermont AM; Bastholt L;
Melanoma Res; 2016 Aug; 26(4):367-76. PubMed ID: 27076041
[TBL] [Abstract][Full Text] [Related]
17. Tumor Microvessel Density as a Potential Predictive Marker for Bevacizumab Benefit: GOG-0218 Biomarker Analyses.
Bais C; Mueller B; Brady MF; Mannel RS; Burger RA; Wei W; Marien KM; Kockx MM; Husain A; Birrer MJ;
J Natl Cancer Inst; 2017 Nov; 109(11):. PubMed ID: 29059426
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of human epididymis protein 4 in epithelial ovarian cancer.
Paek J; Lee SH; Yim GW; Lee M; Kim YJ; Nam EJ; Kim SW; Kim YT
Eur J Obstet Gynecol Reprod Biol; 2011 Oct; 158(2):338-42. PubMed ID: 21683503
[TBL] [Abstract][Full Text] [Related]
19. Preoperative serum YKL-40 is a marker for detection and prognosis of endometrial cancer.
Diefenbach CS; Shah Z; Iasonos A; Barakat RR; Levine DA; Aghajanian C; Sabbatini P; Hensley ML; Konner J; Tew W; Spriggs D; Fleisher M; Thaler H; Dupont J
Gynecol Oncol; 2007 Feb; 104(2):435-42. PubMed ID: 17023034
[TBL] [Abstract][Full Text] [Related]
20. Serum Vascular Endothelial Growth Factor-A as a Prognostic Biomarker for Epithelial Ovarian Cancer.
Komatsu H; Oishi T; Itamochi H; Shimada M; Sato S; Chikumi J; Sato S; Nonaka M; Sawada M; Wakahara M; Umekita Y; Harada T
Int J Gynecol Cancer; 2017 Sep; 27(7):1325-1332. PubMed ID: 28557832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]